ID   HCC827EPR
AC   CVCL_V407
DR   cancercelllines; CVCL_V407
DR   Wikidata; Q54881809
RX   PubMed=21062933;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_114785; Erlotinib.
CC   Selected for resistance to: ChEBI; CHEBI_90197; PHA-665752.
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2063 ! HCC827
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 19-12-24; Version: 15
CH   CVCL_V406 ! HCC827CLR
//
RX   PubMed=21062933; DOI=10.1158/1078-0432.CCR-10-1371;
RA   Suda, Kenichi
RA   Murakami, Isao
RA   Katayama, Tatsuya
RA   Tomizawa, Kenji
RA   Osada, Hirotaka
RA   Sekido, Yoshitaka
RA   Maehara, Yoshihiko
RA   Yatabe, Yasushi
RA   Mitsudomi, Tetsuya
RT   "Reciprocal and complementary role of MET amplification and EGFR T790M
RT   mutation in acquired resistance to kinase inhibitors in lung cancer.";
RL   Clin. Cancer Res. 16:5489-5498(2010).
//